Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01466153 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 183
- Enrollment target
NCT01466153 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 183 participants.
The verdict
NCT01466153, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 183 participants
- Enrollment target
Study Summary
The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell Transplant (ASCT), had superior efficacy compared to rituximab in the same population.
Interventions
- DRUG Rituximab
- DRUG Bendamustine
- DRUG MEDI-551
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2012-02-07 |
| Est. Completion | 2016-01-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01466153
The ClinicalTrials.gov registry entry for NCT01466153 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT01466153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01466153 about?
NCT01466153 is a clinical study titled "A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)". The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell Transplant (ASCT), had superior efficacy compared to rituximab in the same po...
What is the current status of trial NCT01466153?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2012-02-07. Estimated completion is 2016-01-08.
What interventions are being tested in trial NCT01466153?
The interventions under investigation include: Rituximab (DRUG), Bendamustine (DRUG), MEDI-551 (DRUG).
Who is sponsoring clinical trial NCT01466153?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.